Living Well: A Digital ACT Intervention

Overview

Depression and anxiety are frequently comorbid and share mechanisms contributing to dysfunction. Transdiagnostic approaches, such as Acceptance and Commitment Therapy, streamline intervention and allow a broader population to benefit in a cost-effective fashion. Brief ACT interventions targeting at-risk individuals have the potential to prevent negative outcomes. Delivering these in a digital format overcomes attitudinal and structural barriers to accessing treatment.

Full Title of Study: “Living Well: A Digital Acceptance and Commitment Therapy-Informed Intervention”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2022

Detailed Description

Depression and anxiety disorders are among the most prevalent psychological difficulties and contribute to negative economic, social, and health outcomes. As they are frequently comorbid and share underlying mechanisms of dysfunction, many scholars have conceptualized these as a unified category of emotional disorders. Addressing processes contributing to dysfunction among individuals who are at risk for developing emotional disorders has the potential to prevent significant negative impact. Acceptance and Commitment Therapy (ACT) has received empirical support in the treatment of depression and anxiety in a number of examinations. ACT aims to shape acceptance of challenging thoughts and feelings and engagement with areas of life one finds meaningful and important. The converse of acceptance, experiential avoidance, or the unwillingness to experience unpleasant thoughts and emotions even when doing so is maladaptive, has been predictive of symptoms of depression and anxiety. Reducing experiential avoidance and shaping alternative responses, such as acceptance and behavior consistent with one's values, termed committed action, is a promising strategy for targeting risk for emotional disorders. Traditional means of delivering interventions fail to reach a substantial proportion of those who struggle with psychological difficulties. Barriers such as distance, time, and cost contribute to these challenges. Digital mental health interventions offer a means to overcome treatment barriers and increase access. These approaches can be delivered in individual's homes at the time of their choosing. Additionally, digital interventions can be delivered to many people at the same time, reducing cost. Support for the impact of ACT-informed digital interventions on symptoms of depression and anxiety has been obtained, suggesting that this framework is promising for reducing risk. The goal of the current study is to compare the impact of a digital ACT-informed intervention on psychological symptoms and processes of change among individuals at risk for depression and anxiety. The following hypotheses will be evaluated: 1. Individuals in the treatment condition will experience a decrease in symptoms of depression and anxiety compared to those in the control group 2. Individuals in the treatment condition will experience a decrease in experiential avoidance and increase in values consistent behavior compared to those in the control group 3. The digital intervention will generally be rated positively 4. The relationship between cognitive fusion and treatment response will be explored

Interventions

  • Behavioral: Living Well
    • Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.

Arms, Groups and Cohorts

  • Experimental: Living Well Intervention Group
    • Participants in the Living Well treatment group will receive a brief digital intervention informed by Acceptance and Commitment Therapy.
  • No Intervention: Control Group
    • Participants in the control group will not receive any intervention. These individuals will have the option to access the intervention at the conclusion of their study participation.

Clinical Trial Outcome Measures

Primary Measures

  • Depression Anxiety Stress Scales-21 Depression Scale repeated measure of change
    • Time Frame: pre-intervention, two week post intervention, and four week post intervention
    • Depression Anxiety Stress Scales-21 (DASS-21) is a 21 item self report questionnaire assessing symptoms of depression, anxiety, and stress. The DASS-21 seven item Depression Scale will be used to assess symptoms of depression and with higher scores indicating greater depressive symptoms. Scores on the DASS-21 Depression Scale range from 0 to 21.
  • Depression Anxiety Stress Scales-21 Anxiety Scale repeated measure of change
    • Time Frame: pre-intervention, two week post intervention, and four week post intervention
    • Depression Anxiety Stress Scales-21 (DASS-21) is a 21 item self report questionnaire assessing symptoms of depression, anxiety, and stress. The DASS-21 seven item Anxiety Scale will be used to assess symptoms of anxiety with higher scores indicating greater anxiety symptoms. Scores on the DASS-21 Anxiety Scale range from 0 to 21.
  • Brief Experiential Avoidance Questionnaire repeated measure of change
    • Time Frame: pre-intervention, two week post intervention, and four week post intervention
    • Brief Experiential Avoidance Questionnaire (BEAQ) is a 15 item self report measure assessing experiential avoidance. Higher scores on the BEAQ indicate greater experiential avoidance. Scores on the BEAQ can range from 15 to 90.
  • Valuing Questionnaire-Progress Scale repeated measure of change
    • Time Frame: pre-intervention, two week post intervention, and four week post intervention
    • Valuing Questionnaire-Progress Scale (VQ-P) is a five item scale assessing the extent to which one made progress towards one’s values that is a part of the ten item Valuing Questionnaire. Higher scores on the VQ-P indicate greater progress towards one’s values and VQ-P scores can range from 0 to 30.

Participating in This Clinical Trial

Inclusion Criteria

  • Undergraduate students aged 18 or older – Mildly to moderately elevated symptoms of depression or anxiety as reflected by DASS-21 Depression (5-10) or Anxiety scores (4-7). Exclusion Criteria:

  • Participants under the age of 18 – Severe or extremely severe scores on DASS-21 Depression (11 or greater) or Anxiety (8 or greater).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Texas at Tyler
  • Provider of Information About this Clinical Study
    • Principal Investigator: Olga Berkout, Assistant Professor of Psychology – University of Texas at Tyler
  • Overall Official(s)
    • Olga Berkout, PhD, Principal Investigator, University of Texas at Tyler

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.